{"url_path":"/sec/inkt/8-k/2026-05-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-225369-index.html","accession_number":"0001193125-26-225369","cik":"0001840229","ticker":"INKT","issuer_name":"MiNK Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-225369-index.html","primary_entity_key":"0001840229","primary_entity_name":"MiNK Therapeutics, Inc."},"word_count":65,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\nThe following exhibit is furnished herewith:\n\n99.1 [Press Release dated May 15, 2026](inkt-ex99_1.htm)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate:\n\nMay 15, 2026\n\nBy:\n\n/s/ Jennifer S. Buell\n\n \n\n \n\n \n\nJennifer S. Buell, Chief Executive Officer"}